Physician profile
Kevin N Gitlin
NPI 1447340229
$1,387.34
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $45.23 · 2021: $824 · 2023: $41.95 · 2024: $14.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salvin Dental Specialties, INC. | $571.18 | 2021 | |
| Allergan, INC. | $234.68 | 2019-2020 | |
| Abbvie INC. | $199.25 | 2021 | |
| Lundbeck LLC | $123.51 | 2019-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $82.04 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.66 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $35.55 | 2019-2023 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $32.04 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.28 | 2023 | |
| Vanda Pharmaceuticals INC. | $14.68 | 2024 | Fanapt |
| Avanir Pharmaceuticals, INC. | $13.38 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gitlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.